Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting

Core Insights - Lantheus Holdings, Inc. is presenting real-world evidence of PYLARIFY's effectiveness in detecting recurrent prostate cancer at the 2025 ASCO Genitourinary Cancers Symposium [1][2] - PYLARIFY is the leading PSMA-targeted PET imaging agent in the U.S., with over 400,000 scans conducted across 48 states [3] Presentation Details - The presentation will occur on February 13, 2025, during two time slots: 11:25 am – 12:45 pm PT and 5:45 PM-6:45 PM PT [2] - The session will include two posters: one on early detection of recurrent prostate cancer and another on the role of conventional imaging and PYLARIFY in prostate cancer patients [2] Product Information - PYLARIFY (piflufolastat F 18) is a PSMA-targeted PET imaging agent that allows visualization of metastatic prostate cancer [3] - The recommended dose for PYLARIFY is 333 MBq (9 mCi), with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi) [3] Company Overview - Lantheus is a leading company in the radiopharmaceutical sector, focused on improving patient outcomes through innovative diagnostic solutions [11]